Metastatic Colorectal Cancer 2.0
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (20 December 2023) | Viewed by 12190
Special Issue Editors
Interests: translational research; biomarkers; liquid biopsy; oncology
Special Issues, Collections and Topics in MDPI journals
Interests: translational research; angiogenesis; colorectal cancer; pancreatic cancer
Special Issues, Collections and Topics in MDPI journals
Interests: molecular biology; oncology; translational research; liquid biopsy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Issue is the second edition of the previous one: "Metastatic Colorectal Cancer" (https://www.mdpi.com/journal/cancers/special_issues/Metastatic_Colorectal_Cancer).
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in males and the second in females. Translational research has led to significant benefits in the management of patients with metastatic disease, and precision medicine is becoming the goal of scientific research.The introduction of molecular targeted or antiangiogenic agents has significantly improved patient outcomes, but predictive markers of efficacy are not completely understood. Furthermore, immune-checkpoint inhibitors have recently made their way broadly into clinical practice.A new approach for biomarker detection is the use of liquid biopsy, which has the potential to replace tumor tissue analysis in clinical practice and can enable the monitoring of the tumor burden as well as the detection of tumor heterogeneity and molecular resistance to therapy.
Dr. Paola Ulivi
Dr. Alessandro Passardi
Dr. Giorgia Marisi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- targeted therapy
- biomarkers
- angiogenesis
- EGFR pathways
- circulating tumor cells
- tumor heterogeneity
- liquid biopsy
- clinical trials
- molecular pathology